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Abstract
2-Arachidonoylglycerol (2-AG) is an important endogenous
signaling lipid that activates the cannabinoid receptors (CB1R
and CB2R), thereby regulating a diverse range of physiological
processes including anxiety, appetite, inflammation, memory,
pain sensation, and nociception. Diacylglycerol lipases
(DAGLs) are the principle enzymes responsible for 2-AG
biosynthesis. Recently, the (patho)physiological functions of
DAGLs have been explored by both genetic methods and
chemical tools. This review will focus on the recent efforts to
develop highly selective and in vivo active DAGLs inhibitors
using activity-based protein profiling. C© 2017 International Union
of Biochemistry and Molecular Biology, Inc. Volume 65, Number 1, Pages
9–15, 2018
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1. Introduction
Extracts of the plant Cannabis sativa, also known as marijuana,
have been used for recreational and medical purposes for thou-
sands of years [1, 2]. Marijuana affects multiple physiological
processes, including pain sensation, memory, mood, sleep, and
appetite [3]. In 1964, the structure of 9-tetrahydrocannabinol
(9-THC; Fig. 1), the principal psychoactive component of C.
sativa, was reported [4]. It took almost 30 years to identify
the target protein (termed cannabinoid CB1 receptor) that is
activated by 9-THC [5]. The CB1 receptor belongs to the family
of G-protein-coupled receptors and is expressed in neurons, as-
trocytes, and microglial cells in various brain regions, including
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cerebellum, hippocampus, basal ganglia, cortex, amygdala, hy-
pothalamus, and thalamus [6]. In neurons, the cannabinoid CB1
receptor is often located at presynaptic membranes, possibly
also in mitochondria [7], and its activation by 9-THC results
in reduction of intracellular cAMP levels, activation of inward-
rectifying K+ channels, and inhibition of voltage-sensitive Ca2+
channels, thereby inhibiting neurotransmitter release and
modulation of synaptic plasticity. A second 9-THC-binding
protein, the cannabinoid CB2 receptor, was identified in 1993
[8]. It is primarily found in peripheral immune cells [9, 10],
such as B-cells, macrophages, and monocytes. Activation of the
CB2 receptor exerts immunosuppressive effects [11].
The discovery of cannabinoid CB1 receptor initiated
the search for endogenous compounds in mammals that
could activate this protein. In 1992, the first endoge-
nous ligand was discovered and named anandamide (N-
arachidonoylethanolamine, AEA; Fig. 1), which is derived
from the Sanskrit word for bliss [12]. Three years after the
discovery of AEA, 2-arachidonoylglycerol (2-AG; Fig. 1), a com-
mon intermediate in phospholipid and triglyceride metabolism,
was reported as the second endogenous lipid that modulated
cannabinoid CB1 receptor function [13]. 2-AG and AEA are
the most abundant endogenous ligands of the cannabinoid
receptors and are termed “endocannabinoids.” Some other
lipids, such as 2-arachidonoylglycerylether (noladin ether),
O-arachidonoylethanolamine (O-AEA, virodhamine), and N-
arachidonoyl-dopamine (NADA), have also been reported to
activate the cannabinoid receptors, but their role as endo-





Chemical structures of THC and the two most















Chemical structures of some other putative
endocannabinoids: Noladin ether, virodhamine
(O-AEA), and NADA.
FIG. 3
A schematic view of endocannabinoid signaling.
Glutamate released from the excitatory axon
terminal activates type I metabotropic glutamate
receptor (mGluR), which stimulates 2-AG
production through the phospholipase C and
DAGL pathway. 2-AG then crosses the synaptic
cleft and activates presynaptic CB1 receptors,
which induces the suppression of glutamate or
γ -aminobutyric acid (GABA) release.
AEA and 2-AG are often found together, but their individual
levels vary between cell types, brain regions, tissues, species,
developmental stages, and pathological conditions [16–18]. En-
docannabinoids play an essential role in the brain by activating
the cannabinoid CB1 receptor in different brain cells. They
modulate neurotransmitter release (Fig. 3) and regulate many
physiological processes, including pain perception, learning
and memory, energy balance, emotional states (anxiety, fear),
and reward-related behavior [19]. The exact contribution of
each individual endocannabinoid in specific brain regions
to these (patho)physiological functions remains, however, is
poorly understood.
Continuous activation of the CB1 receptor by endocannabi-
noids is associated with nicotine addiction, obesity, and the
metabolic syndrome [20, 21]. Endocannabinoids play also an
important role during neurodegeneration and inflammation
[22–24]. All of these are major risk factors for illness and
death. The CB1 receptor antagonist rimonabant was effective
in obese patients, but was withdrawn from the market due to
unacceptable psychiatric side effects (depression and suicidal
ideation in some individuals) [25]. This highlights the medical
need to understand modulation of the endocannabinoid lev-
els in the brain in a more detailed manner. Inhibitors of the
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FIG. 4
Biosynthetic and metabolic pathways of 2-AG.
biosynthetic enzymes of the endocannabinoids would provide
valuable tools to study the role of each endocannabinoid in the
various physiological processes. This review will focus on the
enzymes that control 2-AG production. Activity-based protein
profiling (ABPP) is applied as a chemoproteomic method to
identify inhibitors of these enzymes to modulate cannabinoid
CB1 receptor activation by 2-AG.
2. Diacylglycerol Lipases
2-AG is produced from membrane phospholipids via a two-step
process starting with sn-2 arachidonoyl phosphatidylinositol
4,5-bisphosphate (PIP2) (Figs. 3 and 4) [26]. In the first step,
PIP2 is hydrolyzed into arachidonyl-containing diacylglycerol
(DAG) species by phospholipase Cβ (PLCβ), which is activated
by various G-protein-coupled receptors. The second step is
catalyzed by diacylglycerol lipase (DAGL), in which DAG is
converted into 2-AG in a sn-1 specific manner [27, 28]. In
addition, there are some other proposed pathways for 2-AG
synthesis [29, 30]. For example, hydrolysis of 2-arachidonoyl-
LPA by an LPA phosphatase may also provide 2-AG (Fig. 4)
[29].
The rate-limiting step in 2-AG production is controlled
by two homologous isoforms of DAGLs, DAGLα (120 kDa)
and DAGLβ (70 kDa) [27]. Both proteins are multidomain
membrane-spanning enzymes that belong to the serine hydro-
lase family and differ from each other by the presence of a long
C-terminal tail (300 amino acids) in DAGLα. This C-terminal
tail is involved in the regulation of the catalytic activity of the
enzyme [31–33].
Genetic studies with DAGL knockout mice have demon-
strated that DAGLα and DAGLβ regulate 2-AG production in a
tissue-type-dependent manner [32, 34]. DAGLα is the principal
regulator of 2-AG formation in the nervous system, whereas
DAGLβ is the dominant enzyme for 2-AG production in pe-
ripheral tissues such as the liver. Interestingly, basal brain
anandamide levels are also reduced in DAGLα−/- mice, but not
in DAGLβ−/− mice [35, 36]. Therefore, a pharmacological agent
to modulate DAGLα or DAGLβ activity in an acute and temporal
manner would provide an important counterpart for DAGLα−/–
or DAGLβ−/− mice to study the physiological functions of DAGLs
in complex biological systems.
3. Activity-Based Protein Profiling for
DAGL Inhibitor Discovery and
Optimization
In early studies, the general lipase inhibitors tetrahydrolipstatin
(THL, Orlistat) and RHC-80267, a bis-oximino-carbamate, have
been reported to inhibit DAGL-mediated 2-AG production using
a radiometric assay with 1-[14C]oleoyl-2-arachidonoylglycerol
as natural substrate. They are, however, poorly active and/or
lack the selectivity over other serine hydrolases (Fig. 5) [37–39].




Chemical structures of earlier reported DAGL
inhibitors: RHC80267, THL, O-3640, O-3841, and
O-5596.
FIG. 6
Schematic overview of ABPP. (a) Representative
cartoons of ABPs: reactive group (blue), linker
(gray), and reporter tag (red) (e.g., fluorophore or
biotin affinity tag). (b) ABPs can be used in various
biological systems, including cell/tissue lysates in
vitro, living cellular systems, and in vivo animal
models. (c) In competitive ABPP, proteomes are
preincubated with inhibitors, followed by
coincubation with an ABP. (d) Two-steps probes
(click chemistry ABPP) provide a postdetection of
protein labeling.
In 2006, Bisogno et al. discovered fluorophosphonate inhibitors
against DAGLα (O-3640 and O-3841). These compounds are
active in vitro systems, but are not suitable for in vivo stud-
ies due to their poor stability and lack of cell permeability.68
Further structure–activity relationship studies of fluorophos-
phonate inhibitors led to the discovery of O-5596, which is a
relatively stable and potent DAGLs inhibitor [40]. However,
O-5596 cross-reacts with several off-targets, which prohibits
its use as a specific DAGLs inhibitor.
To study the function of DAGL in native biological systems,
high selectivity, potent, and in vivo active DAGL inhibitors are
required. ABPP, a chemical proteomic technology, has greatly
accelerated the discovery and development of selective and
in vivo active DAGL inhibitors. ABPP allows the study of the
functional state of proteins by chemical probes in a native
cellular context [41, 42]. In contrast to other techniques that
detect messenger RNA or polypeptides/proteins (i.e., in situ
hybridization and immunohistology, respectively), ABPP only
visualizes active proteins and takes all posttranslational mod-
ifications into account. ABPP makes use of organic molecules,
termed activity-based probes (ABPs) to label the active site
of a protein (Fig. 6a). ABPs are tool compounds that cova-
lently and irreversibly inhibit enzymes and that are equipped
with a tag (fluorophore, biotin, bioorthogonal tag) through
which the target enzyme, or enzyme family, is visualized by
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FIG. 7
DAGL inhibitors with high selectivity and/or in vivo
activity. LEI104 and LEI105 are reversible inhibitors
with high selectivity. KT109 and KT172 are
peripherally restricted in vivo active DAGLβ
inhibitors, DH376 and DO34 are CNS-active DAGLs
inhibitors. KT195 and DO53 are control
compounds. HT-01 and DH379 are DAGL-tailored
ABPs.
fluorescence microscopy, or enriched to enable identification
and characterization using chemical proteomics methodology
by mass spectrometry. In comparative ABPP, two biological
samples are interrogated with ABPs. Differences in enzyme
activities are monitored and identified with various ABPs.
Comparative ABPP allows the discovery of targets and vali-
dation of drug–target interaction in live cells, tissue lysates,
and sometimes in animals (Fig. 6b). In competitive ABPP, a
small molecule is preincubated with a biological sample and
residual enzyme activities are subsequently monitored with an
ABP (Fig. 6c). Competitive ABPP can also be used to determine
target engagement in situ and in vivo. In case the ABP fall
short and do not work due to a lack of bioavailability or enzyme
specificity, two-step ABPs can be applied. Two-step ABPs do
not constitute a reporter tag, but instead carry a small ligation
handle, which can be conjugated to a biotin or fluorescent
tag via bio-orthogonal ligation chemistry, only after the ABP
has covalently reacted with the target of interest (Fig. 6d).
These combined ABPP technologies provide a highly attractive
platform, both to discern aberrant enzyme functioning in phys-
iological processes and to identify compounds able to correct
for this.
Using an ABPP screen, Baggelaar et al. discovered α-
ketoheterocycles LEI104 and LEI105 (Fig. 7) as a new chemo-
type of selective, reversible DAGLs inhibitors. LEI104 was
poorly active in a cellular assay and inhibited fatty acid amide
hydrolase (FAAH), the enzyme responsible for the metabolism
of anandamide. LEI105, a derivative of LEI104, was a potent
and highly selective DAGL inhibitor that did not target other
proteins in the endocannabinoid system, including CB1R, CB2R,
ABHD6, ABHD12, FAAH, and monoacylglycerol lipase (MAGL).
However, no in vivo activity has been reported for LEI105 to
date.
In 2012, Hsu et al. published the first in vivo active DAGLβ
inhibitors KT109 and KT172 (Fig. 7), which are based on a
triazole urea scaffold [43]. KT109 and KT172 were 60-fold
selective over DAGLα as determined by ABPP. Both inhibitors
showed high selectivity against DAGLβ over other serine
hydrolases, except for ABHD6. To exclude the effects of ABHD6,
a control compound KT195 (a close structural analog of KT109
and KT172 that did not inhibit DAGLβ, but did inhibit ABHD6)
was applied in their studies. Based on the 1,2,3-triazole urea
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scaffold, Hsu et al. also developed an ABP HT-01 for DAGL,
which was more sensitive for DAGLβ than DAGLα. KT109 and
KT172 selectively inhibit DAGLβ in Neuro2A cells and in mouse
macrophages as determined by ABPP using HT-01 and FP-
biotin. Acute blockade of DAGLβ by KT109 or KT172 reduced
2-AG, arachidonic acid, and eicosanoid levels in Neuro2A
cells, human prostate cancer cells, and mouse peritoneal
macrophages. Additionally, DAGLβ blockade decreased the
levels of the proinflammatory cytokine tumor necrosis factor
α (TNFα) in lipopolysaccharide (LPS)-treated mice. However,
KT109 and KT172 did not cross the blood–brain barrier.
Recently, Ogasawara et al. developed the triazole ureas
DH376 and DO34 as potent brain-active DAGL inhibitors. They
were very selective and displayed only a few off-target ac-
tivity [44], including ABHD6 (DH376, DO34), CES1C (DH376,
DO34), BCHE (DH376), LIPE (DH376), ABHD2 (DO34), PAFAH2
(DO34), and PLA2G7 (DO34). Meanwhile, DO53 was designated
as a paired control compound [44], which showed negligi-
ble activity against DAGLα or DAGLβ, but cross-reacted with
many off-targets of DH376 and DO34. They also reported
the development of DH379, a DAGL-tailored ABP. Pharma-
cological inhibition of DAGLs by DH376 and DO34 induced a
rapid reorganization of lipid signaling networks in the brain,
including reduction in levels of 2-AG, anandamide, arachi-
donic acid, eicosanoids (PGD2 and PGE2), and an elevation
in 1-stearoyl-2-arachidonoyl-sn-glycerol (SAG, C18:0/C20:4)
and 1-oleoyl-2-arachidonoyl-sn-glycerol (DAG, C18:1/C20:4).
The robust alterations of these brain lipids in DH376- and
DO34-treated mice were dose and time dependent and absent
in DO53-treated mice. Of note, most lipid changes in DAGL
inhibitor-treated mice were mirrored by the lipid changes in
DAGLα−/− mice, apart from a reduction in triglycerides. This
indicates that chronic, long-term inhibition of DAGLα might be
needed for triglyceride metabolism. Interestingly, the authors
found that DAGLα is a short half-life protein, which is rapidly
degraded and replaced by newly synthesized enzyme. At the
moment, it is still unclear how the reduction in anandamide
levels, which was observed both in DAGLα−/− mice and in
DAGL inhibitor-treated mice, can be explained. It might be
due to the strong reduction in arachidonic acid, which could
perhaps deplete the pool of arachidonic acid required for the
biosynthesis of the precursor of anandamide, but crosstalk
between DAG-mediated protein kinase C (PKC) signaling and
the enzymes responsible for anandamide biosynthesis is also
an interesting option to explore.
Synaptic plasticity regulated by 2-AG signaling, such as
depolarization-induced suppression of excitation (DSE) and
inhibition (DSI), were fully blocked by both DAGL inhibitors,
but not by DO53. Acute inhibition of DAGL also strongly
suppressed the LPS-induced neuroinflammation as witnessed
by reductions in brain prostaglandin and cytokine levels as
well as reversal of anapyrexia [44]. Interestingly, the reduction
in cytokine levels was also observed with the negative control
compound DO53, suggesting that an additional target may
be involved. Furthermore, Deng et al. found that DH376
temporarily reduced fasting-induced refeeding of mice, thereby
emulating the effect of cannabinoid CB1-receptor inverse
agonists [45]. This was mirrored by the DAGL inhibitor DO34
but also by DO53. The contribution of the off-target(s) shared
by DAGL inhibitors and DO53 in controlling food intake in
fasting-induced mice can thus not be excluded. These results
indicate that DH376 and DO34, along with the control probe
DO53, are important chemical tools for studying diverse aspects
of DAGL function in animals and ex vivo brain preparations.
To conclude, we have reviewed here the use of ABPP in
the development of highly selective DAGL inhibitors, such as
DH376 and DO34. Several studies using these chemical tools
have shown that DAGLs coordinate crosstalk between different
lipid-signaling networks and modulate neuro(immuno)logical
functions in the brain. However, to elucidate the specific roles of
DAGLα and DAGLβ in (patho)physiological conditions, subtype-
selective inhibitors are required. Furthermore, the short
half-life of DAGLα also brings some challenges for current set
of inhibitors, and improving the pharmacokinetic properties
of DAGL inhibitors is required to obtain prolonged DAGLα
inhibition in vivo.
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